News
The 1 Thing Missing From Gilead Sciences' 2018 Priority List
At a recent healthcare conference, Gilead Sciences (NASDAQ: GILD) CEO John Milligan laid out his top three priorities for 2018. Here's what he said (this and all other quotes courtesy of S&P....
Better Buy: AbbVie Inc. vs. Johnson & Johnson
They're partners. And they're rivals. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) co-market fast-growing cancer drug Imbruvica. However, the two big drugmakers compete against each....
3 Stocks That Have Doubled and Still Have Room to Grow
The S&P 500 is hovering near an all-time high and has had a great year in 2017, so it's not a surprise that many stocks have delivered exceptional performance recently. However, just because a....
Is Merck & Co. Inc. a Buy?
If 2017 ended right now, it would be the worst year for Merck & Co. (NYSE: MRK) stock since the financial crisis of 2008. There are still several weeks remaining before the year ends, of....
Better Buy: Biogen Inc. vs. Gilead Sciences
Historically, Biogen (NASDAQ: BIIB) has definitely been a better stock than Gilead Sciences (NASDAQ: GILD). Whether you look at the last three, five, 10, 25 years, or even so far in 2017, Biogen....
Here's Why Nektar Therapeutics Is Skyrocketing 70% in November
After the company told investors that it plans to file for Food and Drug Administration approval for a drug that could disrupt the $12 billion market for opioid painkillers, Nektar Therapeutics....
3 Indisputable Reasons Why AbbVie Is the Best Big Pharma Stock
What's the best big pharma stock?Of course, "best" can mean different things to different people. But with stocks, there are key metrics that can be used to determine which are better than others.....
Unternehmensanalyse Gilead Sciences
Gilead Sciences ist ein sehr profitables Unternehmen aus der Pharma- und Biotechnik Branche. Das Unternehmen produziert dabei Medikamente und Präparate für diverse Krankheiten. Die wichtigsten....
Donald Trump's Nominee for HHS Secretary Causes a Tumble in Biotech Stocks
Donald Trump's next top pick for running the Department of Health and Human Services (HHS) is Eli Lilly & Co. (NYSE: LLY) executive Alex Azar, and that's drawing the ire of patient advocates....
3 Top Big Pharma Dividend Stocks You Can Buy Right Now
Big pharma stocks have long been favorites for dividend-seeking investors, and for good reason. Major pharmaceutical companies typically generate strong cash flow, which allows them to pay high....
What Investors Need to Know About Investing in Low PE Stocks
What do Warren Buffett, Ben Graham, Seth Klarman, and Peter Lynch all have in common? Besides being wildly successful investors, they're all are adherents to value investing, a method where one....
Better Buy: Acadia Pharmaceuticals vs. Biogen
A potential rising star or an established leader? That's pretty much the choice for investors considering whether to buy Acadia Pharmaceuticals (NASDAQ: ACAD) or Biogen (NASDAQ: BIIB) stock.So far....
7 Things AbbVie's Top Executives Just Said That You'll Want to Know
It's a good time to be AbbVie (NYSE: ABBV). And with the biotech's share price up more than 50% year to date, it's a good time to be an AbbVie shareholder. The company reported a strong....
Why Macy's, Hostess Brands, and Perrigo Jumped Today
The stock market lost ground Thursday as investors reacted negatively to news regarding proposed U.S. corporate and individual income tax cuts. Reports surfaced that the Senate version of tax....
The Not-So-Subtle Reason Behind Perrigo Company PLC's 13% Move Higher
Shares of Perrigo (NYSE: PRGO), a provider of consumer goods and over-the-counter pharmaceutical products, rocketed higher by as much as 13% during Thursday's trading session after the company....
You'll Be Stunned by Gilead Sciences CEO's Prediction for 2018
No, this isn't one of those clickbait articles you've no doubt seen way too many times. Gilead Sciences (NASDAQ: GILD) CEO John Milligan actually did make a prediction about 2018. And it really....
Here's Why Merck & Co., Inc. Tanked 14% in October
Shares of America's second largest pharmaceutical company, Merck & Co., Inc. (NYSE: MRK) suffered their worst month in years, falling 14% in October, according to data from S&P Global....
The Clear-Cut Reason Alexion Pharmaceuticals Tanked 15% in October
Shares of Alexion Pharmaceuticals (NASDAQ: ALXN), a large-cap biotech company with a focus on rare genetic diseases, tumbled 15% during the month of October, according to data from S&P Global....
Here's Why Regeneron Pharmaceuticals Inc. Slipped 10% in October
Shares of Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) took a hit last month as investors adjusted their outlook for a recently launched eczema drug with megablockbuster potential. According to....
Better Buy: Novavax, Inc. vs. Pfizer Inc.
Pfizer (NYSE: PFE) ranks as one of the giants of the pharmaceutical market, with a blockbuster vaccine franchise. Novavax (NASDAQ: NVAX) is only a fraction of Pfizer's size and is still at least a....
These 3 Stocks Just Raised Their Dividends
Thanksgiving came early to the stock exchange last week, with a score of companies declaring increases in their dividends. To some degree that's expected, given that we're in the swing of the fall....
What's Behind Gilead Sciences Inc.'s $7.8 Billion Slide in October?
Shares of Gilead Sciences, Inc. (NASDAQ: GILD) slipped 7.5% last month, according to S&P Global Market Intelligence, reducing the biotech's market cap by $7.8 billion. Although the company....
5 Things Pfizer's Management Just Said That You Don't Want to Miss
Forget Pfizer's (NYSE: PFE) third-quarter earnings announcement. The real story lies in what the company's top executives said afterward.The big pharma company reported its third-quarter results....
Pfizer Inc. (PFE) Q3 2017 Earnings Conference Call Transcript
Image source: The Motley Fool.Pfizer Inc. (NYSE: PFE)Q3 2017 Earnings Conference CallOct. 31, 2017, 8:00 a.m. EDTOperatorContinue readingSource: Fool.com
Seattle Genetics, Inc.: Double-Digit Revenue Growth, but the Best Is Yet to Come
Sales of Seattle Genetics's (NASDAQ: SGEN) Adcetris in the U.S. and Canada jumped 13% year over year in the third quarter, but it's still a relatively small seller for a cancer drug, especially....